Main challenges to cancer care in Latin America: an analysis through breast cancer lenses
- PMID: 40585556
- PMCID: PMC12205613
- DOI: 10.1016/j.lana.2025.101147
Main challenges to cancer care in Latin America: an analysis through breast cancer lenses
Abstract
The manuscript underscores the intricate challenges in breast cancer (BC) care across Latin America, characterized by economic, social, and healthcare system disparities. Limited high-quality cancer registries hinder research and policy development, exacerbating uneven access to medical care and BC mortality disparities. The healthcare systems' fragmentation results in delays in critical interventions, affecting a significant proportion of young women diagnosed at advanced stages. The scarcity of comprehensive healthcare data and the absence of coordinated efforts intensify these challenges. The manuscript advocates for collaborative initiatives, supporting local research groups and fostering communication among countries to address BC care disparities. It emphasizes the vital role of national care plans and universal healthcare systems, aligning with global objectives to reduce BC mortality and enhance healthcare access for all women in Latin America, irrespective of socioeconomic status.
Keywords: Breast cancer; Breast cancer early detection; Cancer care access; Health system disparities; Latin America; Resource-stratified guidelines.
© 2025 The Authors.
Conflict of interest statement
GGA: declares consulting fees from Novartis, AstraZeneca, Roche, Pfizer, Lilly, and MSD; honoraria from Novartis, AstraZeneca, Lilly, MSD, and GlaxoSmithKline; support for attending meetings and/or travel from AstraZeneca, Novartis, Gador, Raffo, and GlaxoSmithKline; and participation on data safety monitoring or advisory boards for Novartis, AstraZeneca, Roche, Pfizer, Lilly, and MSD. PM: declares consulting fees from Novartis, AstraZeneca, Roche and MSD; honoraria from Novartis, AstraZeneca, Roche, Pfizer and MSD; support for attending meetings and/or travel from Novartis, AstraZeneca and Roche. GC: declares participation at Advisory Boards for Roche, Novartis, Lilly, Pfizer, Astra Zeneca, Daichii Sankyo, Ellipsis, Veracyte, Exact Science, Celcuity, Merck, BMS, Gilead, Sanofi, and Menarini. CHB: declares consulting fees from Boehringer-Ingelheim, GSK, Novartis, Pfizer, Roche/Genentech, Eisai, Bayer, MSD, Astra Zeneca, Zodiac, Lilly, Sanofi, and Daiichi; honoraria from Gilead, GSK, Novartis, Pfizer, Roche/Genentech, Eisai, Bayer, MSD, Astra Zeneca, Zodiac, Lilly, Sanofi, and Daiichi; support for attending meetings and/or travel from Gilead, Novartis, Pfizer, Roche/Genentech, MSD, Astra Zeneca, Lilly, Sanofi, Daiichi, and Roche; participation on a Data Safety Monitoring Board or Advisory Board for Gilead, Novartis, Pfizer, Roche/Genentech, MSD, Astra Zeneca, Lilly, Sanofi, Daiichi, and Roche; and stock or stock options in MED SIR and Thummi.
Figures
References
-
- Buteau A.C., Castelo-Loureiro A., Barragan-Carrillo R., et al. Disparities in cancer control in Central America and the Caribbean. Hematol Oncol Clin North Am. 2024;38(1):35–53. - PubMed
-
- Riano I., Velazquez A.I., Viola L., et al. State of cancer control in South America: challenges and advancement strategies. Hematol Oncol Clin North Am. 2024;38(1):55–76. - PubMed
-
- Barrios C.H., Werutsky G., Mohar A., et al. Cancer control in Latin America and the Caribbean: recent advances and opportunities to move forward. Lancet Oncol. 2021;22(11):e474–e487. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
